This site is intended for healthcare professionals
Journals
  • Home
  • /
  • Journals
  • /
  • Alopecia Areata
  • /
  • Treatment of pediatric alopecia areata: A systemat...
Journal

Treatment of pediatric alopecia areata: A systematic review

Read time: 1 mins
Published:1st Jun 2022
Author: Barton VR, Toussi A, Awasthi S, Kiuru M.
Availability: Free full text
Ref.:J Am Acad Dermatol. 2022 Jun;86(6):1318-1334.
DOI:10.1016/j.jaad.2021.04.077
Treatment of pediatric alopecia areata: A systematic review


Background:
Alopecia areata (AA) is an autoimmune, nonscarring hair loss disorder with slightly greater prevalence in children than adults. Various treatment modalities exist; however, their evidence in pediatric AA patients is lacking.

Objective: To evaluate the evidence of current treatment modalities for pediatric AA.

Methods: We conducted a systematic review on the PubMed database in October 2019 for all published articles involving patients <18 years old. Articles discussing AA treatment in pediatric patients were included, as were articles discussing both pediatric and adult patients, if data on individual pediatric patients were available.

Results: Inclusion criteria were met by 122 total reports discussing 1032 patients. Reports consisted of 2 randomized controlled trials, 4 prospective comparative cohorts, 83 case series, 2 case-control studies, and 31 case reports. Included articles assessed the use of aloe, apremilast, anthralin, anti-interferon gamma antibodies, botulinum toxin, corticosteroids, contact immunotherapies, cryotherapy, hydroxychloroquine, hypnotherapy, imiquimod, Janus kinase inhibitors, laser and light therapy, methotrexate, minoxidil, phototherapy, psychotherapy, prostaglandin analogs, sulfasalazine, topical calcineurin inhibitors, topical nitrogen mustard, and ustekinumab.

Limitations: English-only articles with full texts were used. Manuscripts with adult and pediatric data were only incorporated if individual-level data for pediatric patients were provided. No meta-analysis was performed.

Conclusion: Topical corticosteroids are the preferred first-line treatment for pediatric AA, as they hold the highest level of evidence, followed by contact immunotherapy. More clinical trials and comparative studies are needed to further guide management of pediatric AA and to promote the potential use of pre-existing, low-cost, and novel therapies, including Janus kinase inhibitors.


Read abstract on library site    Access full article